UC Johns Hopkins Glioblastoma Nanofiber Treatment

Researchers from the University of Cincinnati>>> and Johns Hopkins School of Medicine have developed a novel nanofiber drug delivery system for treating Glioblastoma, an aggressive form of brain cancer. The system embeds a combination of three federally approved drugs (temozolomide, acriflavine, and PT2385) into electrospun fiber membranes, demonstrating synergistic effects that are more effective than individual drug administration. Lead author Daewoo Han>>> and Professor Andrew Steckl>>> from the University of Cincinnati>>> led the development of this NanoMesh system, designed for localized, long-term drug delivery directly at the tumor site after surgery. Collaborators from Johns Hopkins School of Medicine, including Betty Tyler>>> and Hasan Sildak>>>, contributed to the research. Animal trials showed significant improvement in survival rates for treated mice, with 40% surviving past 120 days, compared to untreated mice dying within 19 days. The research, supported by a grant from the United States — National Institutes of Health>>>, was published in ACS Biomaterials Science & Engineering. This breakthrough addresses challenges like tumor recurrence and the blood-brain barrier, offering potential for improved patient survival and quality of life.